Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 20/20 | 0.88 |
| ▸ | CHD1 | O14646 | 2/20 | 0.72 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382706 | 1.00 | EHMT2 (0.88) | EHMT2CHD1EHMT1 | |
| SCHEMBL25229558 | 0.98 | EHMT2 (0.83) | EHMT2CHD1EHMT1 | |
| SCHEMBL29382797 | 0.98 | EHMT2 (0.83) | EHMT2CHD1EHMT1 | |
| SCHEMBL25239670 | 0.96 | EHMT2 (0.80) | EHMT2CHD1EHMT1 | |
| SCHEMBL29384861 | 0.95 | EHMT2 (0.81) | EHMT2CHD1EHMT1 | |
| SCHEMBL25231361 | 0.95 | EHMT2 (0.81) | EHMT2CHD1EHMT1 | |
| SCHEMBL29385290 | 0.94 | EHMT2 (0.79) | EHMT2CHD1EHMT1 | |
| SCHEMBL25204677 | 0.94 | EHMT2 (0.79) | EHMT2CHD1EHMT1 | |
| SCHEMBL25243208 | 0.94 | EHMT2 (0.88) | EHMT2EHMT1 | |
| SCHEMBL29385010 | 0.94 | EHMT2 (0.88) | EHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11485728-B2 | Small molecules for the treatment of autoimmune diseases and cancer | ATHOS THERAPEUTICS, INC. (US) | 2022-11-01 | — | — | US | claimed |
| US-20220073498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2022-03-10 | — | — | US | claimed |
| CN-116323587-A | Small molecules for autoimmune diseases and cancer treatment | 阿索斯治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4192826-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | Athos Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11485728-B2 | Small molecules for the treatment of autoimmune diseases and cancer | ATHOS THERAPEUTICS, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220073498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | SSB, HLA-DRB1, UACA | EHMT2 1523/4885CHD1 3110/4885EHMT1 1748/4885 |
| US-11485728-B2 | Small molecules for the treatment of autoimmune diseases and cancer | SSB, HLA-DRB1, UACA | EHMT2 1523/4885CHD1 3110/4885EHMT1 1748/4885 |
| US-20220073498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | SSB, HLA-DRB1, UACA | EHMT2 1523/4885CHD1 3110/4885EHMT1 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.